S&P 500 7,641 -2.02% Nasdaq 26,067 -2.75% Dow Jones 52,759 -2.01% FTSE 100 10,781 +0.29% DAX 26,056 -1.45% Nikkei 225 66,016 -4.63% Hang Seng 25,974 +3.41% WTI Crude 86.41 +2.26% Gold 4,620 +4.59% US 10-Year Treasury Yield 4.696 +0.00% S&P 500 7,641 -2.02% Nasdaq 26,067 -2.75% Dow Jones 52,759 -2.01% FTSE 100 10,781 +0.29% DAX 26,056 -1.45% Nikkei 225 66,016 -4.63% Hang Seng 25,974 +3.41% WTI Crude 86.41 +2.26% Gold 4,620 +4.59% US 10-Year Treasury Yield 4.696 +0.00%

LATEST

Dangote offers East African countries 30% stake in planned $17 billion refinery●Otedola’s net worth nears $2 billion after $500 million gain YTD●Bitcoin ETFs draw $608M as Ether ETFs see largest inflow since October●Kenya Moved Three Railway Loans Out of Dollars and Into Yuan●West Africa’s Shared Stock Market Just Passed US$35 Billion for the First Time●For city gas distributors, policy support is short-term relief, at best●ChatGPT gains access to Apple Messages, raises privacy concerns●AI's Bar Mitzvah moment: Aswath Damodaran explains what AI means for businesses●Dangote offers East African countries 30% stake in planned $17 billion refinery●Otedola’s net worth nears $2 billion after $500 million gain YTD●Bitcoin ETFs draw $608M as Ether ETFs see largest inflow since October●Kenya Moved Three Railway Loans Out of Dollars and Into Yuan●West Africa’s Shared Stock Market Just Passed US$35 Billion for the First Time●For city gas distributors, policy support is short-term relief, at best●ChatGPT gains access to Apple Messages, raises privacy concerns●AI's Bar Mitzvah moment: Aswath Damodaran explains what AI means for businesses●

Asia

Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target

Markets-Economic Times · 2h ago · 🇮🇳 India

Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target

Jefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is bullish on the company’s integrated CRDMO model, strong return ratios and growth prospects, forecasting 18% revenue CAGR through FY29. Key triggers include new commercial molecules and biosimilar launches, while customer concentration and high capex remain key risks.

Read the full story at Markets-Economic Times →

More Asia

For city gas distributors, policy support is short-term relief, at best

mint - markets · 29m ago

AI's Bar Mitzvah moment: Aswath Damodaran explains what AI means for businesses

Markets-Economic Times · 35m ago

PSU banks offer highest alpha potential; IT faces uncertainty: Omniscience Capital

Markets-Economic Times · 37m ago

MCX shares jump 8% in 3 days as gold, silver futures rise. What lies ahead for investors?

Markets-Economic Times · 41m ago